The Global Health Body Sounds Alert Over Acute Shortage of Obesity Jabs
Less than 10% of individuals that would benefit from weight-loss injections such as Wegovy can access them, warns the WHO as it issues its inaugural advice on the medications.
Given in excess of 1,000,000,000 people worldwide currently classified as obese, it is urging more widespread and fairer availability to these injectable treatments.
According to forecasts, over two billion could be obese by 2030 without intervention.
"Our latest guidelines acknowledges that obesity is a long-term condition that can be addressed with thorough and lifelong support," stated its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and supply-chain constraints are key hurdles to broad availability to the injections that can assist patients in reducing considerable body mass, explains the organization.
GLP-1 Therapy Scarcity
Despite the present best projected scenario, the manufacturing of these medications might only reach around 100 million people – fewer than 10% of the global need, per the health organization.
The recommendation calls on countries and companies to increase access, through approaches like licensing agreements.
Exclusive production rights on the active ingredient – the main component of Novo Nordisk's Wegovy – is scheduled to end in multiple nations in 2026.
How Obesity Drugs Work
The injections replicate a biological compound to reduce digestion speed, curb appetite and boost feelings of fullness so individuals eat less.
Patients usually see weight reduction in the initial weeks of beginning the regular doses.
Evidence indicates patients may put most of the weight back on a year later of halting the medication, when their typical food cravings return.
To be carrying excess weight raises your chance for experiencing diseases, including diabetes, heart disease, stroke, and some cancers.
Excess weight affects individuals in countries worldwide and was linked to 3.7 million fatalities worldwide in 2024, according to the health agency.
